Alliance for Biopharmaceutical Competitiveness and Innovation
Biopharmaceutical industry
Based in DC
🤖
AI Overview
With $7.0M in lobbying spend across 33 quarterly filings, Alliance for Biopharmaceutical Competitiveness and Innovation is one of the biggest lobbying spenders in Washington. Their lobbying covers 1 issue area. Active from 2018 to 2025.
$7.0M
Total Spend
8
Years Active
1
Firms Hired
6
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $570K |
| 2019 | $510K |
| 2020 | $590K |
| 2021 | $800K |
| 2022 | $960K |
| 2023 | $1.0M |
| 2024 | $1.5M |
| 2025 | $1.0M |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Taxation
- •Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965. Issues related to Puerto Rico.
- •Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965. Issues related to Puerto Rico incentive
- •Issues related to corporate and international tax including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965. Issues related to Puerto Rico incentives and ex
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.